News

In its pivotal Phase 3 study, arimoclomol (MIPLYFFA) halted disease progression versus placebo over 12 months on the NPC...

No new efficacy or safety numbers were disclosed. Still, AAVantgarde Bio will present updated Phase 1/2 LUCE-1 data for...

Anavex Life Sciences has published preclinical data in •iScience• further elucidating the mechanism by which its SIGMAR1 (S1R) agonist,...

Incannex Healthcare’s Phase 2 trial of PSX-001 (formerly Psi-GAD), a psilocybin-assisted therapy for generalized anxiety disorder (GAD), demonstrated statistically...

Marker Therapeutics’ Phase 1 APOLLO study of MT-601 in relapsed B-cell lymphoma patients yielded a 66% objective response rate...

Cemdisiran monotherapy, administered subcutaneously every three months, demonstrated a 2.3-point placebo-adjusted improvement in the Myasthenia Gravis Activities of Daily...

BioXcel Therapeutics’ BXCL501, a sublingual dexmedetomidine film, met its primary endpoint of tolerability in the SERENITY At-Home Phase 3...

In Stage A of a Phase 3 trial in China, RemeGen’s telitacicept achieved a 55% reduction in 24-hour urine...

Life Biosciences’ preclinical data from the ARDD meeting showcase promising results for its Partial Epigenetic Reprogramming (PER) platform in...

Memgen has dosed the first patient in a Phase 1 combination cohort evaluating its oncolytic immunotherapy MEM-288 alongside docetaxel...